Patent intelligence · US
US 11739132
Separation moieties and methods of use thereof
Separation moieties and methods of use thereof
Patent details — US 11739132
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 29, 2023
- Expiration
- Aug 24, 2043
- Applicant
- Werewolf Therapeutics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K47/642
Quick answer
US 11739132 (Separation moieties and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Aug 29, 2023. Expires Aug 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Werewolf Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K47/642
More from Werewolf Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12275769
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 12076371
Activatable cytokine polypeptides and methods of use thereof
granted -
US 12036266
Activatable cytokine polypeptides and methods of use thereof
granted -
US 11981716
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11535658
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11453710
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 11352403
Activatable interleukin-2 polypeptides and methods of use thereof
granted
Frequently asked questions
What is US patent 11739132?
US 11739132 (Separation moieties and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Aug 29, 2023. Expires Aug 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11739132?
Werewolf Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 11739132 expire?
Our index shows an expiration date of Aug 24, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.